1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Takes First Step For Lynparza/Imfinzi Combo In Ovarian Cancer

First PARP plus PD1/L1-inhibitor Combo Data

 
• By Alexandra Shimmings

Combining a PARP inhibitor with a checkpoint inhibitor could improve outcomes in ovarian cancer patients, hint the early data from AstraZeneca’s Phase III DUO-O study of Lynparza and Imfinzi. How much broader a market now beckons for the two drugs remains uncertain, however.    

Female Reproductive System_1200
• Source: Shutterstock

A first look at the data from the Phase III DUO-O study of AstraZeneca PLC’s Lynparza and Imfinzi in newly diagnosed ovarian cancer suggest the combination could have benefit in delaying disease progression, but its commercial potential is likely to depend on upcoming overall survival and subgroup data.

The DUO-O trial is testing the PARP inhibitor Lynparza (olaparib) with the anti-PD-L1 Imfinzi (durvalumab) together with the VEGF inhibitor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

More from R&D